《2022年国际立场声明：人血白蛋白在肝硬化相关并发症治疗中的应用》摘译

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：白朝辉、祁兴顺负责摘译；杨永平、杨丽负责审校。

详细信息

An excerpt of use of albumin infusion for cirrhosis-related complications: an international position statement in 2022

1.
Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China
2.
Department of Hepatology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
3.
Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China

摘要: 近期，来自19个国家的33名具有肝硬化相关并发症管理专业知识的研究人员经过三轮德尔菲法提出了12项有关人血白蛋白在肝硬化相关并发症治疗中应用的国际立场声明。本文对该部国际立场声明的主要内容进行中文摘译。
- 肝硬化 /
- 血清白蛋白, 人 /
- 共识
Abstract: Recently, 33 investigators from 19 countries with expertise in managing cirrhosis-related complications have proposed 12 international position statements regarding the use of human albumin infusion for cirrhosis-related complications after a three-round Delphi consensus process. This article gives an excerpt of the main contents of this international position statement in Chinese language.
- Liver Cirrhosis /
- Serum Albumin, Human /
- Consensus

表 1 评分标准

Table 1. Five-point Likert scales

观点	非常赞成	赞成	中立	不赞成	非常不赞成	弃权
分数	5分	4分	3分	2分	1分	不表达意向

下载: 导出CSV

表 2 共识程度评估标准

Table 2. Definitions of consensus degree

下载: 导出CSV

[1]	BAI Z, MÉNDEZ-SÁNCHEZ N, ROMEIRO FG, et al. Use of albumin infusion for cirrhosis-related complications: an international position statement[J]. JHEP Rep, 2023, 5(8): 100785. DOI: 10.1016/j.jhepr.2023.100785.